V
Vassiliki Poulaki
Researcher at Boston University
Publications - 74
Citations - 11611
Vassiliki Poulaki is an academic researcher from Boston University. The author has contributed to research in topics: Apoptosis & Fas ligand. The author has an hindex of 47, co-authored 74 publications receiving 11196 citations. Previous affiliations of Vassiliki Poulaki include Massachusetts Eye and Ear Infirmary & University of Cologne.
Papers
More filters
Journal ArticleDOI
A central role for inflammation in the pathogenesis of diabetic retinopathy
Antonia M. Joussen,Vassiliki Poulaki,Minh Ly Le,Kan Koizumi,Christina Esser,Hanna Janicki,Ulrich Schraermeyer,Norbert Kociok,Sascha Fauser,Bernd Kirchhof,Timothy S. Kern,Anthony P. Adamis +11 more
TL;DR: It is shown that chronic, low‐grade subclinical inflammation is responsible for many of the signature vascular lesions of diabetic retinopathy, highlighting the central and causal role of adherent leukocytes in the pathogenesis of diabetes.
Journal ArticleDOI
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Nicholas Mitsiades,Constantine S. Mitsiades,Vassiliki Poulaki,Dharminder Chauhan,Galinos Fanourakis,Xuesong Gu,Charles G. Bailey,Marie Joseph,Towia A. Libermann,Steven P. Treon,Nikhil C. Munshi,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson +13 more
TL;DR: The molecular sequelae of PS-341 treatment in MM cells are characterized and the rationale for future clinical trials of this promising agent, in combination with conventional and novel therapies, to improve patient outcome in MM is explained.
Journal ArticleDOI
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Nicholas Mitsiades,Constantine S. Mitsiades,Paul G. Richardson,Vassiliki Poulaki,Yu-Tzu Tai,Dharminder Chauhan,Galinos Fanourakis,Xuesong Gu,Charles G. Bailey,Marie Joseph,Towia A. Libermann,Robert L. Schlossman,Nikhil C. Munshi,Teru Hideshima,Kenneth C. Anderson +14 more
TL;DR: This study found that subtoxic concentrations of PS-341 potently sensitized MM cell lines and patient cells to DNA-damaging chemotherapeutic agents such as doxorubicin and melphalan, including cells resistant to these drugs and those isolated from a patient who had relapsed afterPS-341 monotherapy.
Journal ArticleDOI
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
Nicholas Mitsiades,Constantine S. Mitsiades,Vassiliki Poulaki,Dharminder Chauhan,Paul G. Richardson,Teru Hideshima,Nikhil C. Munshi,Steven P. Treon,Kenneth C. Anderson +8 more
TL;DR: The mechanism of action of IMiDs against MM cells in vitro is delineated and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM.
Journal ArticleDOI
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Constantine S. Mitsiades,Nicholas Mitsiades,Nicholas Mitsiades,Ciaran J. McMullan,Vassiliki Poulaki,Vassiliki Poulaki,Reshma Shringarpure,Masaharu Akiyama,Teru Hideshima,Dharminder Chauhan,Marie Joseph,Marie Joseph,Towia A. Libermann,Towia A. Libermann,Carlos Garcia-Echeverria,Mark A. Pearson,Francesco Hofmann,Kenneth C. Anderson,Andrew L. Kung +18 more
TL;DR: NVP-ADW742 monotherapy or its combination with cytotoxic chemotherapy had significant antitumor activity in an orthotopic xenograft MM model, providing in vivo proof of principle for therapeutic use of selective IGF-1R inhibitors in cancer.